Armata Pharmaceuticals (ARMP)
(Real Time Quote from BATS)
$3.15 USD
+0.03 (0.96%)
Updated Oct 6, 2025 03:52 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ARMP 3.15 +0.03(0.96%)
Will ARMP be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ARMP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARMP
Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year?
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year?
ARMP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
All You Need to Know About Armata Pharmaceuticals (ARMP) Rating Upgrade to Buy
Is Armata Pharmaceuticals (ARMP) Outperforming Other Medical Stocks This Year?
Other News for ARMP
Is ARMP preparing to trend higher? New 52 Week Closing High shows up after advancing 1.63%
Is ARMP poised for gains? Crossed Above 20 Day Moving Average shows up after gaining 3.71%
Is ARMP showing downside potential? Fell Below 20 Day Moving Average shows up after slipping 0.7%
Is ARMP gaining bullish strength? Pocket Pivot shows up after advancing 1.02%
Is ARMP showing upside potential? 20 Day Moving Average Support shows up after declining 1.99%